Publication of a Real-World Study Supports an Immunotherapy in a Highly Competitive Market

A leading biopharma company needed to build market share for an anti-PD-1 immunotherapy in a highly competitive immuno-oncology space. Utilizing observational analysis of patients identified by the iKnowMed^℠ oncology EHR, McKesson helped the biopharma company conduct a real-world study of the effectiveness of pembrolizumab, which was recently published in the Journal of Immunotherapy.